AKAliki Korkontzelou

Aliki Korkontzelou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aliki Korkontzelou has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic Changes Following Smoking Cessation in Patients with Type 2 Diabetes Mellitus

    by Stamatina Driva, Aliki Korkontzelou, Serena Tonstad, Nikolaos Tentolouris, Eleni Litsiou, Vasiliki Vasileiou, Alice G. Vassiliou, Vassiliki Saltagianni, Paraskevi Katsaounou

    Background: Smoking cessation is crucial for reducing complications of type 2 diabetes mellitus (T2DM), but associated weight gain can worsen glycemic control, discouraging quitting attempts. Varenicline, a partial agonist of α4β2 nicotinic receptors, aids smoking cessation. This study examines the effects of varenicline on body weight and metabolic parameters in patients with T2DM and prediabetes. Methods: Fifty-three patients were enrolled, of which 32 successfully quit smoking after a three-month course of varenicline and were examined after an additional month with no medication. Measurements taken at baseline, 2.5 months, and 4 months included body weight, blood pressure, resting metabolic rate (RMR), glycated hemoglobin (HbA1c), fasting glucose, blood lipids, C-reactive protein (CRP), appetite-related hormones, and physical activity. Results: Post-treatment, there were no significant changes in body weight, blood pressure, RMR, or glycemic control. Total (CHOL) and low-density lipoprotein (LDL-C) cholesterol decreased significantly at 4 months of the study (from 168 to 156 mg/dL, p = 0.013, and from 96 to 83 mg/dL, p = 0.013, respectively). Leptin levels increased (from 11 to 13.8 ng/dL, p = 0.004), as did glucagon-like peptide-1 (GLP-1) levels (from 39.6 to 45.8 pM, p = 0.016) at 4 months of follow-up. The percentage of participants who reported moderate-intensity activity increased from 28% to 56%, while those reporting high-intensity activity increased from 19% to 22%, respectively (p = 0.039). Conclusions: Our study showed that smoking cessation with varenicline in smokers with T2DM and prediabetes led to significant improvements in lipid profile, significant increase in plasma leptin and GLP-1 levels, and increased physical activity, without significant weight gain. Thus, smoking cessation without weight gain or deteriorated glycemic control is feasible for these smokers, with added benefits to lipid profiles, GLP-1 regulation, and physical activity.


  • Open Access

    Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study

    by Paschalis Steiropoulos, Niki Georgatou, George Krommidas, Konstantinos Bartziokas, Aliki Korkontzelou, Panos Katerelos, Petros Efstathopoulos, Dimosthenis Papapetrou, Stavros Theodorakis, Konstantinos Porpodis

    Background: The extrafine single inhaler triple therapy (efSITT) containing beclomethasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg has proved to be efficacious in patients with chronic obstructive pulmonary disease (COPD) in randomized control trials. Objective: TRIWIN study evaluated the effectiveness of efSITT delivering beclomethasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg in COPD patients previously treated with multiple-inhaler triple therapy (MITT) in a real-world study in Greece. Design: Prospective, multicenter, observational, non-interventional study was conducted over 24 weeks. Methods: A total of 475 eligible patients had moderate-to-severe COPD, an indication for treatment with efSITT, and were symptomatic despite receiving MITT. COPD Assessment Test (CAT) score, pulmonary function parameters, use of rescue medication, and adherence to inhaler use were recorded at baseline (Visit 1), 3 (Visit 2), and 6 months (Visit 3) after treatment. Results: Mean CAT score decreased from 21.4 points at Visit 1, to 16.6 at Visit 2 and 15.1 at Visit 3 ( p < 0.001 for all pair comparisons). At Visit 3, 79.8% of patients reached a CAT improvement exceeding minimal clinically important difference (⩾2), compared to baseline. Mean forced expiratory volume in 1 s (%pred.) increased from 55.4% at Visit 1 to 63.5% at the end of study period ( p < 0.001), while mean forced vital capacity (%pred.) increased from 71.1% at Visit 1, to 76.7% at Visit 3 ( p < 0.001). The mean Test of Adherence to Inhalers score increased from 42.5 to 45.3 and 46.3 points, for the three visits, respectively ( p < 0.001 comparing Visits 1/2 and Visits 1/3; p = 0.006 comparing Visits 2/3). The percentage of patients showing good adherence rose from 33.7% at baseline to 58.3% at Visit 3. The percentage of patients using rescue medication during the last month dropped from 16.2% to 7.4% at the end of study period ( p < 0.001). Pulmonary function parameters also improved. Conclusion: The TRIWIN results suggest that extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium is effective in improving health status, pulmonary function, and adherence and in reducing rescue medication use in COPD patients previously treated with MITT, in a real-world setting in Greece.


  • Open Access

    “Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study – The TRIBUNE study”

    by Konstantinos Porpodis, Konstantinos Bartziokas, Panagiotis Chatziapostolou, Aliki Korkontzelou, Panos Katerelos, Petros Efstathopoulos, Petros Bakakos


  • Open Access

    ERS International Congress 2022: highlights from the Epidemiology and Environment Assembly

    by James G.H. Parkin, Laura Delgado-Ortiz, Rosalie Delvert, Manosij Ghosh, Aliki Korkontzelou, Sarang Patil, Marine Savouré, Mateusz Jankowski, Orianne Dumas

    In this article, early career members of the Epidemiology and Environment Assembly of the European Respiratory Society summarise a selection of five sessions from the Society's 2022 International Congress, with a focus on areas of specific interest for the Assembly,i.e.epidemiology and risk factors of respiratory diseases in both children and adults. Topics covered include the characterisation of obstructive respiratory diseases, their comorbidities and their evolution, with novel insight from large cohorts. The importance of early-life factors in respiratory health was also emphasised, including maternal exposures and habits during pregnancy. As smoking behaviours have changed following the introduction of e-cigarettes and heated tobacco products, research remains very active to determine the health consequences and predictors of these novel uses, especially in teenagers. The impact of environmental and occupational exposures on respiratory health remained a major topic of the congress, with a focus on emerging risk factors such as landscape fire smoke, non-exhaust particles and nanoparticles. Regarding workplace exposures, old and novel causes of occupational asthma and rhinitis were discussed.


  • Open Access

    DETERMINATION OF GREENHOUSE GASES EMISSIONS FROM PMDI PRODUCTS IN GREECE

    by Thodoros Glytsos, Elena Mammi-Galani, Eleftheria Chalvatzaki, Aliki Korkontzelou, Vasilis Letsios, Spiros Alexandrakis, Michalis Lazaridis

  • Open Access

    The Effect of Smoking Cessation on Body Weight and Other Metabolic Parameters with Focus on People with Type 2 Diabetes Mellitus

    by Stamatina Driva, Aliki Korkontzelou, Serena Tonstad, Nikolaos Tentolouris, Paraskevi Katsaounou

    Smokers with diabetes mellitus substantially lower their risks of microvascular and macrovascular diabetic complications, in particular cardiovascular disease, by quitting smoking. However, subsequent post-smoking-cessation weight gain may attenuate some of the beneficial effects of smoking cessation and discourage attempts to quit. Weight gain can temporarily exacerbate diabetes and deteriorate glycemic control and metabolic profile. The molecular mechanisms by which quitting smoking leads to weight gain are largely associated with the removal of nicotine’s effects on the central nervous system. This review addresses mechanisms of post-smoking-cessation weight gain, by reviewing the effects of nicotine on appetite, food intake, eating behaviour, energy expenditure, fat oxidation and appetite-regulating peptides. We also highlight correlations between post-cessation weight gain and risk of type 2 diabetes, consequences of weight gain in people with type 2 diabetes and the role of pharmacotherapies, which combine treatment of nicotine addiction and promotion of weight control.


  • Open Access

    Diabetics can quit without gaining weight

    by Aliki Korkontzelou, Driva Stamatina, Sotiria Schoretsaniti, Zafeiria Barbaressou, Vasiliki Vasileiou, Vasiliki Saltagianni, Alexander Osarogue, Sotirios Gyftopoulos, Martha Andritsou, Sofia Pappa, et al.

    Background: Post cessation weight gain (PSWG) is typical when quitting smoking, unmotivates smokers to quit and may lead to relapses. PSWG is of considerable concern not only among women but also among smokers with diabetes mellitus, additionally arguing this could further disturb glycemic...

  • The majority of patients that suffer an asthma attack at the Emergency Room (ER) are mild asthmatics

    by Zafeiria Barmparessou, Aliki Korkontzelou, Marios Ioannou, Nikos Vichos, Margarita Gkotsina, Katerina Mprinia, Vasiliki Saltagianni, Timoleon Giannakas, Vassilis Giannakoulis, Nikolaos Athanasiou, et al.

    Introduction: Asthma attacks constitute a major cause of Emergency Room (ER) visits and a potential danger to patients9 life. Additionally, asthma exacerbations pose a severe economic burden for public health. Consequently, identifying the specific characteristics of this patient subgroup may lead to better patient management and subsequently less asthma attacks occurrence. Methods: Patients treated for an asthma exacerbation at the ER during four months (2019) were assessed for a definite asthma diagnosis at the outpatient clinic. The study included patients that the diagnosis of asthma was confirmed. Parameters reported at Figure 1a. Results: A total of 70 patients were enrolled, with 36,2% of them having an asthma diagnosis for the first time. Reexamination, carried out at least 3 months after the attack, revealed that the majority of patients had mild asthma. Specifically, 73,5% had stage I or II, 9,4% stage III and only 17% stage IV or V. Hospital admission occurred in 13,3% of patients (of which 50% stage I-II, 13% stage III and 37% of stage IV-V). Among patients with a previous diagnosis of asthma, prescribed medication included ICS-LABA (16,8%), ICS-LABA & LAMA (10%), SABA monotherapy (26,6%) whereas 30% did not receive any medication. 25,5% were exposed to passive smoking. Specific characteristics available at Figure 1b. Conclusion: The vast majority of patients with asthma attacks visiting ER were either not diagnosed for asthma or if they were diagnosed, they abused SABA and lacked proper medication. Most of them belong to stage II. Smoking, psychopathology, poor therapy adherence, lack of action plan and a new diagnosis where the most common characteristics.


  • Smoking cessation in patients with Diabetes Mellitus (DM)

    by Aliki Korkontzelou, Stamatina Driva, Sotiria Schoretsaniti, Sotiris Gyftopoulos, Vasiliki Vasileiou, Zafeiria Barbaressou, Alexander Osarogue, Vasiliki Saltagianni, Martha Andritsou, Sofia Pappa, et al.

    Smoking is associated with impaired fasting glucose levels and increased insulin resistance.Post-cessation weight gain (PSWG) highly concerns diabetic patients since it leads to poor control of diabetic parameters, discourages them to quit and can be a cause of relapse. Identification of this population9s characteristics could help improve smoking cessation rates. We recruited smokers with DM (type 1 and 2), who agreed to take varenicline and attend an intense smoking cessation program once a week given by multidisciplinary team. 41 (14 women, 27 men) diabetic smokers accepted to follow the program. The participants were very addicted (FTND 9/11, 30cigs/day), motivated (8,1/10) but lacking confidence (5,1/10). Characteristics shown on Fig 1a. After 3 months 25 participants quit smoking (61%), 7 reduced more than half the cigarettes smoked daily, while 9 participants quit the program. Interestingly, patients who quit the program showed higher levels of psychopathology compared to those who continued. Changes of body weight and rest metabolism rate (RMR) were not significant after smoking cessation (RMR measurements for DM 2 only, N=21) (Fig 1b). HDL was significantly increased. Findings were partly attributed to an increase of physical activity level reported after strong recommendations (Fig 1c). Diabetics succeeded in quitting (61%), ameliorated lipidemic profile, without a statistically significant PSWG by improving physical activity.

  • Increasing smoking cessation (SC) rates through Facebook (FB). ("ToKANA")

    by Aliki Korkontzelou, Zafeiria Barmparessou, Martha Andritsou, Eleni Biniari, Ourania Koltsida, Sotiria Schoretsaniti, Athina Diamanti, Nikolaos Athanasiou, Paraskevi Katsaounou

    There is evidence that social media offer a great field for successful health interventions through enhancement of commitment and social support. FΒ was shown to be a feasible and acceptable environment to achieve smoking cessation interventions. We present the case of 12 smokers attending the SC outpatient clinic that additionally created a FB closed-group, in a self-motivated attempt to support each other. All smokers (characteristics shown at table 1), attended 4 behavioral counseling sessions and 91% used pharmaceutical treatment and followed for additionally 3 months. They all consider themselves to be skilled FB users with 66% reporting daily use of social media. 53% of the participants mentioned that they attended the closed-group daily, while the rest around 3 times a week, all of them both sharing posts and “liking” others’ posts. 83% succeeded in quitting in 4 months and still are participating at the group. All of the members reported that participation in such a group can play a supplemental role to the outpatient clinic, but all rejected replacement of in person visits. 58% believe that this could substitute some visits saving time, though not at the beginning of their attempt. All of them believe that their engagement to this group reinforced their attempts for smoking cessation. This case further supports evidence that FB-group based interventions enhance engagement to smoking cessation.